VSV-EBOPLUS brings together 11 leading international, both clinical and high-tech, vaccine research institutes and non-profit organization from 5 EU countries, Brazil and clinical sites in USA and Africa. The partners provide state-of-the art facilities and clinical vaccination research infrastructures that will work together to facilitate Ebola vaccine development.
The VSV-EBOPLUS project is coordinated by the Sclavo Vaccines Association (www.sclavo.org), a non-profit organization devoted to support research and development of human vaccines.
| Sclavo Vaccines Association (SVA) | Italy |  |
| University of Geneva (UNIGE) | Switzerland |  |
| Merck Sharp & Dohme Corp. (MSD) | USA |  |
| University of Gothenburg (UGOT) | Sweden |  |
| University of Siena (UNISI) | Italy |  |
| Academisch Ziekenhuis Leiden (LUMC) | The Netherlands |  |
| MICROBIOTEC srl (MBT) | Italy |  |
| Eberhard Karls Universitaet Tuebingen (EKUT) | Germany |  |
| Universidade De Sao Paulo (USP) | Brazil |  |
| Spiez Laboratory, Federal Office for Civil Protection (VBS-LS) | Switzerland |  |
| Centre de Recherches Médicales de Lambaréné (CERMEL) | Gabon |  |